Common Fund Program Lifecycle
Strategic Planning: Phases 1 and 2
The Common Fund is intended to be a flexible resource for NIH to make strategic investments in programs that will have high impact NIH-wide. Strategic planning is undertaken regularly to identify research areas that address key roadblocks in biomedical research or that represent emerging scientific opportunities ripe for Common Fund investment.
Strategic planning involves the identification of trans-NIH challenges and opportunities that address the Common Fund criteria. Broad topics identified in Phase 1 are refined into a series of well-defined programs and initiatives in Phase 2. The Council of Councils for the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) acts as an external advisory panel to the DPCPSI and NIH Directors for consideration of Phase 1 concepts.
FY 2014 Strategic Planning updates!
As part of Phase 1 planning for potential new Common Fund programs in fiscal year 2014, the NIH conducted several strategic planning activities in the spring of 2012. In order to hear from people with differing viewpoints, including persons in academic research, private sector research, government agencies, non-profit organizations, and the interested public, the NIH conducted two public meetings in Chicago and San Francisco. Additionally, an invited meeting was also held in Potomac, MD, consisting of participants selected on the basis of their recognition as leaders and innovators in a range of biomedical research areas. Participants in all three meetings articulated pressing challenges facing health research or emerging opportunities where strategic investments might have a transformative impact. They then voted on the highest impact ideas and refined the top ideas to form a “rough draft” implementation plan.
Ideas emerging from these three meetings, along with ideas submitted by NIH Institutes and Centers, were referred to the Council of Councils for concept clearance. Cleared concepts were reviewed by senior NIH leadership to select several ideas to move on to Phase 2 strategic planning. Three concepts were implemented as programs in FY 2013. These programs are:
One concept, Illuminating the Druggable Genome, is anticipated to be launched in FY 2014, pending availability of funds.
Two topics emerging from the FY 2014 Strategic Planning activities are being implemented as extensions of ongoing Common Fund programs: Epigenomic Pharmacology, within the Epigenomics program; and Management of Chronic Diseases in Clinical Trials, within the Health Care Systems Research Collaboratory program.
As each Common Fund program is unique, the implementation of each program varies. To read more about the currently supported Common Fund programs, see “Common Fund Programs.”
Up to Top